The adjustment in price target by Leerink Partners reflects a minor revision in their valuation of Mirum Pharmaceuticals. While the Outperform rating indicates continued confidence in the company's prospects, the slight reduction in price target may reflect adjustments in market conditions or company-specific factors. However, the impact on the stock price is likely to be neutral in the short term, as the overall positive outlook is maintained.